Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Proteostasis Ther (PTI)

Proteostasis Ther (PTI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 70,438
  • Shares Outstanding, K 52,176
  • Annual Sales, $ 5,000 K
  • Annual Income, $ -59,130 K
  • 60-Month Beta 1.19
  • Price/Sales 13.77
  • Price/Cash Flow N/A
  • Price/Book 1.53

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.23
  • Number of Estimates 2
  • High Estimate -0.17
  • Low Estimate -0.29
  • Prior Year -0.25
  • Growth Rate Est. (year over year) +8.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2600 +8.73%
on 07/15/20
1.8400 -25.54%
on 08/04/20
+0.0800 (+6.20%)
since 07/13/20
3-Month
1.1700 +17.09%
on 05/29/20
1.8400 -25.54%
on 08/04/20
-0.3600 (-20.81%)
since 05/13/20
52-Week
0.6100 +124.59%
on 08/14/19
4.7200 -70.97%
on 12/11/19
+0.6902 (+101.53%)
since 08/13/19

Most Recent Stories

More News
Proteostasis Therapeutics (PTI) Reports Q2 Loss, Misses Revenue Estimates

Proteostasis (PTI) delivered earnings and revenue surprises of 19.05% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

PTI : 1.3700 (+1.48%)
Proteostasis: 2Q Earnings Snapshot

BOSTON (AP) _ Proteostasis Therapeutics Inc. (PTI) on Thursday reported a loss of $8.9 million in its second quarter.

PTI : 1.3700 (+1.48%)
Proteostasis Therapeutics Reports Second Quarter 2020 Financial Results

, /PRNewswire/ -- Proteostasis Therapeutics, Inc. (Nasdaq: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis...

PTI : 1.3700 (+1.48%)
Vertex's Kalydeco Wins Approval in EU for CF in Children

Vertex's (VRTX) Kalydeco gains EU nod for use in cystic fibrosis patients aged from six months to 18 years with the R117H mutation in the CFTR gene.

VRTX : 269.25 (-0.59%)
LGND : 113.11 (+1.21%)
ABBV : 94.66 (-0.89%)
PTI : 1.3700 (+1.48%)
Proteostasis Therapeutics Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders

, /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis...

PTI : 1.3700 (+1.48%)
Proteostasis Therapeutics Announces In Vitro Data for PTI-129 as Potential Treatment Candidate for COVID-19

, /PRNewswire/ -- Proteostasis Therapeutics, Inc. (Nasdaq:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis...

PTI : 1.3700 (+1.48%)
Proteostasis Therapeutics (PTI) Reports Q1 Loss, Lags Revenue Estimates

Proteostasis (PTI) delivered earnings and revenue surprises of 17.39% and -100.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

PTI : 1.3700 (+1.48%)
Proteostasis: 1Q Earnings Snapshot

BOSTON (AP) _ Proteostasis Therapeutics Inc. (PTI) on Friday reported a loss of $9.9 million in its first quarter.

PTI : 1.3700 (+1.48%)
Proteostasis Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

, /PRNewswire/ -- Proteostasis Therapeutics, Inc. (Nasdaq: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis...

PTI : 1.3700 (+1.48%)
Zacks.com featured highlights include: JAKKS, Avinger, Energous, FireEye and Proteostasis

Zacks.com featured highlights include: JAKKS, Avinger, Energous, FireEye and Proteostasis

JAKK : 4.99 (+1.63%)
WATT : 3.47 (+9.12%)
FEYE : 15.12 (+1.07%)
AVGR : 0.5451 (-2.66%)
PTI : 1.3700 (+1.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade PTI with:

Business Summary

Proteostasis Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery and development of novel therapeutics to treat diseases caused by an imbalance in the proteostasis network primarily in the United States. Proteostasis Therapeutics, Inc. is based in Cambridge, Massachusetts....

See More

Key Turning Points

2nd Resistance Point 1.4167
1st Resistance Point 1.3833
Last Price 1.3700
1st Support Level 1.3233
2nd Support Level 1.2967

See More

52-Week High 4.7200
Fibonacci 61.8% 3.1500
Fibonacci 50% 2.6650
Fibonacci 38.2% 2.1800
Last Price 1.3700
52-Week Low 0.6100

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar